Acute Spinal Cord Injury - Pipeline Review, Q2 2011

Global Markets Direct, April 2011, Pages: 65

Acute Spinal Cord Injury - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Acute Spinal Cord Injury - Pipeline Review, Q2 2011', provides an overview of the Acute Spinal Cord Injury therapeutic pipeline. This report provides information on the therapeutic development for Acute Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury. 'Acute Spinal Cord Injury - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Spinal Cord Injury.
- A review of the Acute Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Spinal Cord Injury pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Spinal Cord Injury.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Spinal Cord Injury pipeline depth and focus of Acute Spinal Cord Injury therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Spinal Cord Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Spinal Cord Injury
Acute Spinal Cord Injury Therapeutics under Development by Companies
Acute Spinal Cord Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acute Spinal Cord Injury Therapeutics - Products under Development by Companies
Acute Spinal Cord Injury Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acute Spinal Cord Injury Therapeutics Development
NsGene A/S
Sangamo BioSciences, Inc.
Novartis AG
Alseres Pharmaceuticals, Inc.
Acorda Therapeutics, Inc.
Geron Corporation
Oxygen Biotherapeutics, Inc.
Proneuron Biotechnologies, Inc.
SYGNIS Pharma AG
Noscira, S.A.
AnaMar Medical AB
Neurotech Pharmaceuticals, Inc.
Acute Spinal Cord Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cethrin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Inosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRNOPC1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AX200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxycyte Emulsion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZFP TFs For Nerve Regeneration - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neu2000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OEG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chondroitinase Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chondroitinase Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG-33 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PN277 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATI355 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AX201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granulocyte Colony-Stimulating Factor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ProCord - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Spinal Cord Injury Therapeutics – Drug Profile Updates
Acute Spinal Cord Injury Therapeutics - Discontinued Products
Acute Spinal Cord Injury - Featured News
Mar 14, 2011: StemCells Initiates Neural Stem Cell Trial In Spinal Cord Injury
Dec 07, 2010: StemCells Receives Authorization To Conduct Neural Stem Cell Trial In Spinal Cord Injury
Oct 11, 2010: Geron Initiates Clinical Trial Of Human Embryonic Stem Cell-Based Therapy
Sep 20, 2010: Oxygen Biotherapeutics Amends CRADA With US Navy To Include Preclinical Studies Of Oxycyte For Spinal Cord Injury And Hemorrhagic Shock
Jul 30, 2010: Geron To Proceed With Human Clinical Trial Of GRNOPC1 In Patients With Acute Spinal Cord Injury
Jun 03, 2010: Study Shows Marked Neuroprotective Effects of Oxycyte Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury
May 19, 2009: NsGene Granted European Patent Rights To Its Novel Neurotrophic Factor Meteorin For The Treatment Of Neurological Disorders
Sep 18, 2008: The European Commission Grants Orphan Drug Designation To Cethrin For The Treatment Of Traumatic Spinal Cord Injury (SCI)
Aug 25, 2008: Oxygen Biotherapeutics, Inc. to Meet With FDA to Discuss Proposed Phase II-b Oxycyte Clinical Trial
Apr 24, 2008: Amkor Pharma Completes All Clinical Activities For Its Phase I Study Of Neu2000For Treatment Of Acute Brain Injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Spinal Cord Injury, Q2 2011
Products under Development for Acute Spinal Cord Injury – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
NsGene A/S, 2011
Sangamo BioSciences, Inc., 2011
Novartis AG, 2011
Alseres Pharmaceuticals, Inc., 2011
Acorda Therapeutics, Inc., 2011
Geron Corporation, 2011
Oxygen Biotherapeutics, Inc., 2011
Proneuron Biotechnologies, Inc., 2011
SYGNIS Pharma AG, 2011
Noscira, S.A., 2011
AnaMar Medical AB, 2011
Neurotech Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Acute Spinal Cord Injury Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Acute Spinal Cord Injury, Q2 2011
Products under Development for Acute Spinal Cord Injury – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
• Stem Cell Therapy for Spinal Cord Injury
• Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2013
• Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential
• Acute Spinal Cord Injury - Pipeline Review, Q4 2010
• Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2012
• Acute Lung Injury Global Clinical Trials Review, H2, 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2012
• Lung Injury - Pipeline Review, H2 2012